Alliance A041501 – Temporarily closed

A Phase III Trial To Evaluate The Efficacy Of The Addition Of Inotuzumab Ozogamicin (A Conjugated Anti-CD22 Monoclonal Antibody) To Frontline Therapy In Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL

For more information about this clinical trial, click here

Schema & Eligibility Alliance A041501

Available at:

CoxHealth Medical Center, Springfield, MO
Mercy Hospital, Springfield, MO
Delbert Day Cancer Institute at PCRMC, Rolla, MO
Freeman Health System, Joplin, MO
Good Samaritan Regional Health Center, Mt. Vernon, IL
Mercy Hospital, St. Louis, MO
Mercy Hospital, Oklahoma City, OK
Mosaic Life Care, St. Joseph, MO

Ask your physician about participating in this clinical trial or call us.